Save Studies Locally
We can save your selected studies locally in your browser to enhance your experience. This data stays on your device and is not shared with us or third parties. You can clear this data at any time.
By allowing this, you consent to storing study selections locally on your device. Privacy Policy
How to NavigateEcosystem ConnectDistinguished InvestigatorsGlobal ConferencesRLT EducationRLT ComponentsSponsorsTrial Stats
A Randomized Phase II Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)
Description:
This is an open-label, multi-center, randomized phase II study comparing the Y90 TARE followed by bevacizumab and atezolizumab treatment to the Y90 TARE treatment alone in unresectable advanced stage HCC.
Sponsor:
Aiwu Ruth He, MD
Contacts:
Aiwu R He, MD, PhD (Principal Investigator)rmottier@hoosiercancer.org
317-634-5842 ext 60
Government Study Link:
NCT04541173 - Click here to see study onClinicalTrials.gov
